Display options
Cite
Ledgerwood JE, Hu Z, Costner P, et al. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemp Clin Trials. 2015;44:112-118doi: 10.1016/j.cct.2015.08.006.
Ledgerwood, J. E., Hu, Z., Costner, P., Yamshchikov, G., Enama, M. E., Plummer, S., Hendel, C. S., Holman, L., Larkin, B., Gordon, I., Bailer, R. T., Poretz, D. M., Sarwar, U., Kabadi, A., Koup, R., Mascola, J. R., Graham, B. S. (2015). Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemporary clinical trials, 44112-118. https://doi.org/10.1016/j.cct.2015.08.006
Ledgerwood, Julie E, et al. "Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost." Contemporary clinical trials vol. 44 (2015): 112-118. doi: https://doi.org/10.1016/j.cct.2015.08.006
Ledgerwood JE, Hu Z, Costner P, Yamshchikov G, Enama ME, Plummer S, Hendel CS, Holman L, Larkin B, Gordon I, Bailer RT, Poretz DM, Sarwar U, Kabadi A, Koup R, Mascola JR, Graham BS. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemp Clin Trials. 2015 Sep;44:112-118. doi: 10.1016/j.cct.2015.08.006. Epub 2015 Aug 12. PMID: 26275339; PMCID: PMC4751067.
Copy Download .nbib Format: NLM
Share it on

Contemp Clin Trials. 2015 Sep;44:112-118. doi: 10.1016/j.cct.2015.08.006. Epub 2015 Aug 12.

Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.

Contemporary clinical trials

Julie E Ledgerwood, Zonghui Hu, Pamela Costner, Galina Yamshchikov, Mary E Enama, Sarah Plummer, Cynthia S Hendel, Lasonji Holman, Brenda Larkin, Ingelise Gordon, Robert T Bailer, Donald M Poretz, Uzma Sarwar, Alisha Kabadi, Richard Koup, John R Mascola, Barney S Graham,

Affiliations

  1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address: [email protected].
  2. Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
  3. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
  4. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address: [email protected].
  5. Clinical Alliance for Research and Education - Infectious Diseases (CARE-ID), Annandale, VA 22003, United States.

PMID: 26275339 PMCID: PMC4751067 DOI: 10.1016/j.cct.2015.08.006

Abstract

Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two companion Phase 1 studies, VRC 307 and VRC 309, over sequential seasons (2008-2009 and 2009-2010) in which only the influenza B strain component of the vaccines differed. Objectives were safety and immunogenicity of prime-boost vaccination schedules. A schedule of DNA vaccine encoding for seasonal influenza hemagglutinins (HA) prime followed by seasonal trivalent influenza inactivated vaccine (IIV3) boost (HA DNA-IIV3) was compared to placebo (PBS)-IIV3 or IIV3-IIV3. Cumulatively, 111 adults were randomized to HA DNA-IIV3 (n=66), PBS-IIV3 (n=25) or IIV3-IIV3 (n=20). Safety was assessed by clinical observations, laboratory parameters and 7-day solicited reactogenicity. The seasonal HA DNA prime-IIV3 boost regimen was evaluated as safe and well tolerated. There were no serious adverse events. The local and systemic reactogenicity for HA DNA, IIV and placebo were reported predominantly as none or mild within the first 5days post-vaccination. There was no significant difference in immunogenicity detected between the treatment groups as evaluated by hemagglutination inhibition (HAI) assay. The studies demonstrated the safety and immunogenicity of seasonal HA DNA-IIV3 regimen, but the 3-4week prime-boost interval was suboptimal for improving influenza-specific immune responses. This is consistent with observations in avian H5 DNA vaccine prime-boost studies in which a long interval, but not a short interval, was associated with improved immunogenicity.

TRIAL REGISTRATION: NCT00858611 for VRC 307 and NCT00995982 for VRC 309.

Published by Elsevier Inc.

Keywords: DNA vaccine; Immune response; Seasonal influenza

References

  1. Vaccine. 2008 Nov 25;26(50):6338-43 - PubMed
  2. PLoS One. 2015 Apr 17;10(4):e0123969 - PubMed
  3. J Infect Dis. 2006 Oct 15;194(8):1032-9 - PubMed
  4. N Engl J Med. 2013 Nov 28;369(22):2083-92 - PubMed
  5. J Virol. 2009 May;83(9):4624-30 - PubMed
  6. Lancet Infect Dis. 2012 Jan;12(1):36-44 - PubMed
  7. N Engl J Med. 2008 Jun 12;358(24):2540-3 - PubMed
  8. Clin Vaccine Immunol. 2009 Dec;16(12):1709-19 - PubMed
  9. Sci Transl Med. 2012 Aug 15;4(147):147ra114 - PubMed
  10. Lancet Infect Dis. 2011 Dec;11(12):916-24 - PubMed
  11. PLoS One. 2013;8(2):e55571 - PubMed
  12. J Infect Dis. 2013 Aug 1;208(3):413-7 - PubMed
  13. Contemp Clin Trials. 2012 Sep;33(5):895-902 - PubMed
  14. J Infect Dis. 2011 Jun 15;203(12):1719-28 - PubMed
  15. Pathog Dis. 2015 Mar;73(2):1-8 - PubMed
  16. J Infect Dis. 2007 Dec 15;196(12):1732-40 - PubMed
  17. MMWR Morb Mortal Wkly Rep. 2012 Aug 17;61(32):613-8 - PubMed
  18. Science. 2010 Aug 27;329(5995):1060-4 - PubMed
  19. Vaccine. 2007 Apr 20;25(16):3066-9 - PubMed
  20. Vaccine. 2011 Feb 17;29(9):1844-9 - PubMed
  21. J Immunol. 2011 Sep 15;187(6):3391-401 - PubMed
  22. Clin Vaccine Immunol. 2006 Nov;13(11):1267-77 - PubMed
  23. N Engl J Med. 2009 Nov 12;361(20):1945-52 - PubMed
  24. PLoS One. 2010 Feb 02;5(2):e9015 - PubMed
  25. J Infect Dis. 2013 Aug 1;208(3):418-22 - PubMed
  26. Hum Vaccin. 2009 Sep;5(9):623-6 - PubMed
  27. Clin Vaccine Immunol. 2013 Mar;20(3):397-408 - PubMed
  28. Virus Res. 2004 Jul;103(1-2):91-5 - PubMed
  29. MMWR Morb Mortal Wkly Rep. 2013 Jan 18;62(2):32-5 - PubMed
  30. J Infect Dis. 2011 May 15;203(10):1396-404 - PubMed

Publication Types

Grant support